Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial

Lignende værker

• Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
  af: Xiaotong Li, et al.
  Udgivet: (2019-04-01)
• Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
  af: Li, Xiaotong, et al.
  Udgivet: (2019)
• Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome
  af: Powles, Ryan L., et al.
  Udgivet: (2020)
• SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
  af: Nahleh, Z. A., et al.
  Udgivet: (2016)
• Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
  af: Pelekanou, Vasiliki, et al.
  Udgivet: (2017)